Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...
Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic ...
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...
AbbVie’s deal flop and NFL high-profile draft busts have a lot in common.
Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Bristol-Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Shares were recently up 11% after AbbVie reported ...
The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players ... grew ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback